利拉鲁肽、双歧杆菌三联活菌胶囊用于胰岛素+口服药疗效不佳的肥胖2型糖尿病患者的疗效观察OACSTPCD
Efficacy of Liraglutide and Bifidobacterium Triple Viable Capsules in the Treatment of Obese Type 2 Diabetes Mellitus with Poor Efficacy of Insulin+Oral Drugs
目的:基于血糖漂移、脂肪细胞炎症反应、磷脂酰肌醇3激酶(PI3K)/蛋白激酶B(Akt)通路,探讨利拉鲁肽+双歧杆菌三联活菌胶囊用于胰岛素+口服药疗效不佳的肥胖 2 型糖尿病(T2DM)患者的效果与机制.方法:前瞻性选取 2022 年 6 月至 2023 年6 月该院收治的胰岛素+口服药疗效不佳的肥胖T2DM患者980例,采用单盲法,以随机数字表法分为利拉鲁肽组、联合组,各490例.两组患者均给予胰岛素+口服药;在此基础上,利拉鲁肽组患者给予利拉…查看全部>>
OBJECTIVE:To probe into the efficacy and mechanism of liraglutide+Bifidobacterium triple viable capsules in the treatment of obese type 2 diabetes mellitus(T2DM)with poor efficacy of insulin+oral drugs based on blood glucose excursion,adipocyte inflammatory reaction and phosphatidylinositol 3-kinase(PI3K)/protein kinase B(Akt)pathway.METHODS:A total of 980 patients with obese T2DM with poor efficacy of insulin+oral medication admitted to our hospital from Ju…查看全部>>
刘玉斌;王晓蕴;马凌云
河北省沧州中西医结合医院内分泌糖尿病科,河北 沧州 062650河北省沧州中西医结合医院内分泌糖尿病科,河北 沧州 062650河北省沧州中西医结合医院内分泌糖尿病科,河北 沧州 062650
药学
血糖漂移脂肪细胞PI3K/Akt通路利拉鲁肽双歧杆菌三联活菌胶囊肥胖2型糖尿病
Glucose excursionAdipocytesPI3K/Akt pathwayLiraglutideBifidobacterium triple viable capsuleObesityType 2 diabetes mellitus
《中国医院用药评价与分析》 2024 (7)
818-822,5
2021年度中医药类科研计划课题(No.2021351)
评论